Treatment of Lower Limb Ischaemia Due to Atherosclerosis in Diabetic and Nondiabetic Patients with Iloprost, a Stable Analogue of Prostacyclin
- 18 Downloads
A double-blind placebo controlled study was conducted in patients with advanced peripheral arterial occlusive disease (PAOD) to determine the efficacy and tolerability of iloprost, a stable analogue of prostacyclin (PGI2). 85 men and 43 women (74 of whom were diabetic) with resting pain and/or ischaemic lesions of the lower limbs were enrolled in the study. Iloprost was given daily over 6 hours for 21 days by continuous intravenous infusion. Treatment efficacy was assessed on days 21, 28, 60 and 120. Resting pain was improved with treatment: disappearance of pain at day 28 occurred in 50% of patients in the iloprost group and in 19% in the placebo group (p < 0.05). Analgesic consumption was significantly lower in the iloprost group at day 60. No difference was noted for trophic lesions, mean systolic ankle pressure and transcutaneous oxygen pressure (TCpO2). Clinical tolerability was significantly better in the placebo group. Side effects (headache, flushing, nausea and vomiting) were more frequent in the iloprost group, but the risk: benefit ratio was better with iloprost than with placebo. These results suggest that iloprost may be an alternative to amputation in patients with critical ischaemia who are unsuitable for reconstructive surgery.
KeywordsPGI2 Drug Invest Iloprost Peripheral Arterial Occlusive Disease Analgesic Consumption
Unable to display preview. Download preview PDF.
- Cronenwett JL. The use of prostaglandins PGE1 and PGI2 in peripheral arterial ischaemia. Journal of Vascular Surgery 2: 370–374, 1986Google Scholar
- Fonseca V, Dandona P. Treatment of ischaemic ulceration or rest pain with intravenous iloprost: a double-blind placebo controlled study. British Diabetic Association, Glasgow: 22–24 Mar 1990Google Scholar
- Kaukinen S, Pessi T, Ylitalo P, Krais T, Vapaatalo H, et al. Clinical study on ZK 36374: a new stable prostacyclin analog for treatment of peripheral vascular disease, pp. 23–30, Raven Press, New York, 1985Google Scholar
- Norgren L, Alwmark A, Angqvist KA, Hedberg B, Bergqvist D, et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. A Scandinavian-Polish placebo controlled, randomised multicenter study. European Journal of Vascular Surgery 4: 463–467, 1990PubMedCrossRefGoogle Scholar
- Oberender H, Krais TH, Schäfer M, Belcher G. Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog in severe peripheral arterial disease (PAD). Advances in Prostaglandins, Thromboxane and Leukotriene Research 19: 311–316, 1989Google Scholar
- Schillinger E, Krais TH, Lehmann M, Stock G. Iloprost. In Scriabine (Ed.) New cardiovascular drugs, pp. 209–231, Raven Press, New York, 1986Google Scholar